Luis Paz-Ares

Luis Paz-Ares

UNVERIFIED PROFILE

Are you Luis Paz-Ares?   Register this Author

Register author
Luis Paz-Ares

Luis Paz-Ares

Publications by authors named "Luis Paz-Ares"

Are you Luis Paz-Ares?   Register this Author

100Publications

3431Reads

48Profile Views

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2019 Sep 28. Epub 2019 Sep 28.

From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology-Germans Trias i Pujol Hospital, Badalona (E.C.C.) - all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K.) and the Samsung Medical Center at Sungkyunkwan University School of Medicine (K.P.) - both in Seoul, South Korea; the Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania (A.A.); the Hospital Italiano de Buenos Aires, Buenos Aires (L.L.); Instituto Jalisciense de Cancerologia, Guadalajara, Mexico (E.M.J.); the Saitama Cancer Center, Saitama, Japan (H.S.); Matrai Gyogyintezet, Matrahaza, Hungary (I.A.); Limoges University Hospital, Limoges (A.V.), and Aix-Marseille University, National Center for Scientific Research, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - all in France; Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland (S.P.); Sotiria General Hospital, National and Kapodistrian University of Athens, Athens (K.S.); Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.); Fox Chase Cancer Center, Philadelphia (H.B.); Johns Hopkins Kimmel Cancer Center, Baltimore (J.R.B.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., P.B., S.K.R., R.S.K., F.E.N.); and Winship Cancer Institute, Emory University, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910231DOI Listing
September 2019

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

Lung Cancer 2019 Aug 19;134:245-253. Epub 2019 Jun 19.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.06.007DOI Listing
August 2019

Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.

Clin Lung Cancer 2019 Aug 30. Epub 2019 Aug 30.

Laboratory of Thoracic and Clinical-Translational Oncology, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.08.006DOI Listing
August 2019

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.

Cells 2019 Jul 31;8(8). Epub 2019 Jul 31.

H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8080806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721529PMC
July 2019

A patent review of FGFR4 selective inhibition in cancer (2007-2018).

Expert Opin Ther Pat 2019 06 30;29(6):429-438. Epub 2019 May 30.

b CNIO-H12O Lung Clinical Cancer Research Unit , Fundación de Investigación Biomédica i+12 & Centro Nacional de Investigaciones Oncológicas (CNIO) , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2019.1624720DOI Listing
June 2019

FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.

Lung Cancer 2019 May 8;131:112-121. Epub 2019 Feb 8.

H120-CNIO Lung Cancer Clinical Cancer Research Unit, Fundación de Investigación Biomédica i+12 & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Medical School, Universidad Complutense, Madrid, Spain; CIBERONC, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002193032
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2019.02.007DOI Listing
May 2019

Fra-2-expressing macrophages promote lung fibrosis in mice.

J Clin Invest 2019 05 28;129(8):3293-3309. Epub 2019 May 28.

Laboratory Genes and Disease, Department of Dermatology and Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.jci.org/articles/view/125366
Publisher Site
http://dx.doi.org/10.1172/JCI125366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668681PMC
May 2019

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.

J Thorac Oncol 2019 Apr 9;14(4):641-655. Epub 2019 Jan 9.

H12O-CNIO Lung Cancer Clinical Research Unit, Biomedical Research Foundation i+12, Madrid, Spain; H12O-CNIO Lung Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; CIBERONC, Madrid, Spain; Medical Oncology Department, University Hospital Doce de Octubre Madrid, Spain; Medical School, Complutense University, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.021DOI Listing
April 2019

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncol 2019 Apr 13;15(12):1363-1383. Epub 2019 Feb 13.

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany & Institute of Pharmacology, Johannes Gutenberg-University Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0948DOI Listing
April 2019

Necitumumab for the treatment of advanced non-small-cell lung cancer.

Future Oncol 2019 Mar 3;15(7):705-716. Epub 2018 Dec 3.

Medical Oncology Department, Hospital Universitario 12 de Octubre. Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0594DOI Listing
March 2019

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

N Engl J Med 2018 12 25;379(24):2342-2350. Epub 2018 Sep 25.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), Florida Cancer Specialists, Fleming Island (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga (D.D.), and Sarah Cannon Research Institute, Nashville (D.D., D.R.S.) - both in Tennessee; Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.K.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Adelaide, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukoelln, Berlin (M.W.), and the Lung Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.) - both in Germany; Centre Hospitalier Universitaire de Liège, Liège (M.B.), and University Hospitals KU Leuven, Leuven (J.V.) - both in Belgium; Centre Hospitalier Universitaire de Montpellier and Institut du Cancer de Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); the University of Manchester and the Christie NHS Foundation Trust, Manchester (C.F.-F.), AstraZeneca, Alderley Park (C.W.), and AstraZeneca, Cambridge (M.T.) - all in the United Kingdom; AstraZeneca, Gaithersburg, MD (G.M., P.A.D.); and Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1809697DOI Listing
December 2018

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

N Engl J Med 2018 11 25;379(21):2040-2051. Epub 2018 Sep 25.

From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) - both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) - both in Turkey; Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France (J.M.); Universitätsklinikum Tübingen, Tübingen, Germany (B. Hermes); Jász-Nagykun-Szolnok County Hospital, Szolnok (T.C.), and Országos Korányi TBC és Pulmonológiai Intézet, Budapest (A.F.) - both in Hungary; Oncology Center, Medica Sur Hospital, Mexico City (J.R.-C.); Humber River Regional Hospital, Toronto (J.W.); Sendai Kousei Hospital, Sendai (S.S.), and the Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju, South Korea (K.H.L.); Jilin Cancer Hospital, Changchun, China (Y.C.); University of Turin, Orbassano, Italy (S.N.); Montefiore Medical Center-Albert Einstein College of Medicine, New York (B. Halmos); Merck, Kenilworth, NJ (X.L., G.M.L., B.P.); and the Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland (D.M.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1810865DOI Listing
November 2018

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Clin Lung Cancer 2018 11 26;19(6):e823-e830. Epub 2018 May 26.

Oncology at Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.05.013DOI Listing
November 2018

KRAS-Mutant non-small cell lung cancer: From biology to therapy.

Lung Cancer 2018 10 19;124:53-64. Epub 2018 Jul 19.

Lilly Deutschland GmbH, Werner-Reimers-Strasse 2-4, D-61352 Bad Homburg, Germany; Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.07.013DOI Listing
October 2018

Durvalumab in NSCLC: latest evidence and clinical potential.

Ther Adv Med Oncol 2018 11;10:1758835918804151. Epub 2018 Oct 11.

Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Av. de Córdoba km 5,4, 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918804151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187424PMC
October 2018

Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 09;379(11):1093-1094

Hospital Universitario 12 de Octubre, Madrid, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1808566DOI Listing
September 2018

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.

Thromb Res 2018 07 7;167:50-56. Epub 2018 May 7.

Princess Margaret Cancer Centre, University of Toronto, 610 University Avenue Toronto, Ontario, M5G2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2018.05.004DOI Listing
July 2018

Corrigendum to "Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer".

Dis Markers 2018 8;2018:1404780. Epub 2018 Jul 8.

Medical Oncology Department, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas (CNIO), 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1404780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057326PMC
July 2018

Corrigendum to "Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications".

Dis Markers 2018 19;2018:3714684. Epub 2018 Jul 19.

Medical Oncology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3714684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079511PMC
July 2018

Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern.

Nefrologia 2019 Jan - Feb;39(1):94-96. Epub 2018 Jun 23.

Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2018.05.002DOI Listing
June 2018

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 May 16;378(22):2093-2104. Epub 2018 Apr 16.

From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia, Italy (E.M.); First Department of Oncology, Metropolitan Hospital, Athens, Greece (H.L.); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (S.B.); Fundación Arturo López Pérez, Santiago, Chile (P.S.); Fox Chase Cancer Center, Philadelphia (H.B.); Winship Cancer Institute, Emory University, Atlanta (S.S.R.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.B.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., G.G., H.C., J.S., P.B., D.H., Y.F., F.N.); and Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and CiberOnc, Madrid (L.P.-A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1801946DOI Listing
May 2018

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Mayo Clin Proc 2018 03;93(3):307-320

Department of Health Sciences Research, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2017.10.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870793PMC
March 2018

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

J Thorac Oncol 2018 02 20;13(2):228-236. Epub 2017 Nov 20.

Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.11.109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233716PMC
February 2018

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.

Sci Rep 2018 02 5;8(1):2394. Epub 2018 Feb 5.

Medical Oncology Department, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-20570-3
Publisher Site
http://dx.doi.org/10.1038/s41598-018-20570-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799167PMC
February 2018

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.

Clin Lung Cancer 2018 01 23;19(1):65-73.e7. Epub 2017 Jun 23.

Medical Oncology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación i+12, Madrid, Spain; Lung Cancer Group, Clinical Research Program, CNIO (Centro Nacional de Investigaciones Oncológicas) and Instituto de Investigación i+12, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.06.008DOI Listing
January 2018

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.

Oncotarget 2017 Dec 26;8(62):105196-105210. Epub 2017 Oct 26.

Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Consejo Superior de Investigaciones Científicas, Sevilla, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739631PMC
December 2017

Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.

Clin Lung Cancer 2017 11 10;18(6):667-674.e1. Epub 2017 May 10.

Department of Medical Oncology, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Medical School, Universidad Complutense, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.05.008DOI Listing
November 2017

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

N Engl J Med 2017 11 8;377(20):1919-1929. Epub 2017 Sep 8.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and the Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709937DOI Listing
November 2017

Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain.

Arch Bronconeumol 2017 Oct 14;53(10):568-573. Epub 2017 Apr 14.

Servicio de Neumología, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria, CIBERES, Madrid, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arbres.2017.03.004DOI Listing
October 2017

Treating -mutant NSCLC: latest evidence and clinical consequences.

Ther Adv Med Oncol 2017 Sep 24;9(9):589-597. Epub 2017 Jul 24.

Centro de Investigaciones Biomédicas en Red en Cáncer (CIBER-ONC), Madrid, Spain Servicio de Anatomía Patológica, Hospital Universitario Ramón y Cajal, Universidad de Alcalá (IRYCIS), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017719829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564881PMC
September 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.

Front Med (Lausanne) 2017 5;4:36. Epub 2017 Apr 5.

Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2017.00036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380728PMC
April 2017

Biological therapies in nonsmall cell lung cancer.

Eur Respir J 2017 03 2;49(3). Epub 2017 Mar 2.

Medical Oncology Dept, Hospital Universitario 12 de Octubre and Instituto de Investigación i+12, Madrid, Spain

View Article

Download full-text PDF

Source
http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01520
Publisher Site
http://dx.doi.org/10.1183/13993003.01520-2016DOI Listing
March 2017

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.

Dis Markers 2016 30;2016:2138627. Epub 2016 Jun 30.

Medical Oncology Department, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas (CNIO), 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/2138627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944034PMC
February 2017

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.

Dis Markers 2016 26;2016:9214056. Epub 2016 Jul 26.

Medical Oncology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Mardid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/9214056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977389PMC
February 2017

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

J Clin Oncol 2017 Feb 12;35(4):412-420. Epub 2016 Dec 12.

David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2160DOI Listing
February 2017

Lung cancer: current therapies and new targeted treatments.

Lancet 2017 01 27;389(10066):299-311. Epub 2016 Aug 27.

Medical Oncology Department, Hospital Universitario Doce de Octubre and CNIO, Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(
Web Search
http://dx.doi.org/10.1016/S0140-6736(16)30958-8DOI Listing
January 2017

Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat.

Lancet Oncol 2016 12 14;17(12):1622-1623. Epub 2016 Oct 14.

Hospital Universitario Doce de Octubre & Instituto de Investigación i+12, 28041 Madrid, Spain; Unidad de Cáncer de Pulmón, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30506-XDOI Listing
December 2016

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Med Oncol 2016 Oct 27;33(10):105. Epub 2016 Aug 27.

Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-016-0824-yDOI Listing
October 2016

Current Challenges in Cancer Treatment.

Clin Ther 2016 Jul 2;38(7):1551-66. Epub 2016 May 2.

Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación I+12. Lung Cancer Clinical Research Unit CNIO, I+12, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2016.03.026DOI Listing
July 2016

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.

Eur Respir Rev 2016 Mar;25(139):71-6

Dept of Medical Oncology, Virgen del Rocio Teaching Hospital, Instituto de Biomedicina de Sevilla - IBIS, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/16000617.0071-2015DOI Listing
March 2016

Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?

Transl Lung Cancer Res 2016 Feb;5(1):95-7

Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.08.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758970PMC
February 2016